

ERRATUM

Open Access



Erratum to: Clinical trial considerations on male contraception and collection of pregnancy information from female partner: update

Maria Longauer Banholzer^{1*}, Christoph Wandel¹, Paul Barrow³, Marie Mannino², Georg Schmitt³, Melanie Guérard³, Lutz Müller³, Gerard Greig⁴, Kenjie Amemiya⁵, Richard Peck⁴, Thomas Singer³ and Lucette Doessegger⁶

Erratum to: *Clin Trans Med* (2016) 5:23 DOI 10.1186/s40169-016-0103-8

Following publication of the original article in *Clinical and Translational Medicine* [1], it was brought to our attention that there is an error in the section “Safety margin considerations”.

The second sentence of the first paragraph of the section “Safety margin considerations” currently reads: “For first-in-human studies applying a range of escalating doses, the FDA suggests a default safety factor of ten between the exposure for the starting dose and that of the Human Equivalent Dose, which should be individualized [27]”.

This text should read: For first-in-human studies applying a range of escalating doses, the FDA suggests a default safety factor of ten between the NOAEL in GLP toxicology studies in animals and the starting dose expressed as Human Equivalent Dose of the first-in-human study. The safety margin should be individualized by compound [27].

Author details

¹ Safety Risk Management, Licensing & Early Development, F. Hoffmann-La Roche AG, Basel, Switzerland. ² Safety Risk Management, Licensing & Early Development, F. Hoffmann-La Roche Ltd, New York, NY, USA. ³ Pharma Research & Early Development, Roche Innovation Center Basel, Pharmaceutical Sciences, F. Hoffmann-La Roche AG, Basel, Switzerland. ⁴ Pharma Research & Early Development, Roche Innovation Center Basel, Clinical Pharmacology, F. Hoffmann-La Roche AG, Basel, Switzerland. ⁵ Non-Clinical Safety Department, Genentech Inc, South San Francisco, CA, USA. ⁶ Zurich, Switzerland.

The online version of the original article can be found under doi:[10.1186/s40169-016-0103-8](https://doi.org/10.1186/s40169-016-0103-8).

Received: 29 July 2016 Accepted: 2 August 2016

Published online: 12 August 2016

Reference

1. Banholzer ML, Wandel C, Barrow P, Mannino M, Schmitt G, Guérard M, Müller L, Greig G, Amemiya K, Peck R, Singer T, Doessegger L (2016) Clinical trial considerations on male contraception and collection of pregnancy information from female partner: update. *Clin Transl Med* 5:23

*Correspondence: maria.longauer_banholzer@roche.com

¹ Safety Risk Management, Licensing & Early Development, F. Hoffmann-La Roche AG, Basel, Switzerland

Full list of author information is available at the end of the article